Liminatus Pharma Inc. (NASDAQ:LIMN) Short Interest Update

Liminatus Pharma Inc. (NASDAQ:LIMN) was the recipient of a significant decline in short interest in August. As of August 31st, there was short interest totaling 95,505 shares, a decline of 99.1% from the August 15th total of 10,331,073 shares. Based on an average daily volume of 71,248 shares, the short-interest ratio is presently 1.3 days. Approximately 8.8% of the company’s stock are sold short.

Liminatus Pharma Trading Up 4.3%

Shares of LIMN traded up $0.15 during trading hours on Thursday, reaching $3.63. The stock had a trading volume of 19,007 shares, compared to its average volume of 619,206. The firm has a 50-day simple moving average of $5.35 and a 200 day simple moving average of $7.89. Liminatus Pharma has a 12 month low of $3.42 and a 12 month high of $141.50. The company has a market capitalization of $4.86 million, a price-to-earnings ratio of -0.15 and a beta of 5.30.

Liminatus Pharma (NASDAQ:LIMN) last announced its quarterly earnings results on Friday, August 14th. The company reported ($1.50) EPS for the quarter.

Wall Street Analyst Weigh In

LIMN has been the topic of a number of research analyst reports. Weiss Ratings cut shares of Liminatus Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd. Wall Street Zen lowered Liminatus Pharma to a “strong sell” rating in a research report on Saturday, August 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

Liminatus Pharma Company Profile

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.